Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc
Bullboard Posts
User Avatar Image
(37)
•••
Comment by wagyusteakon Jul 22, 2020 4:24pm
42 Views
Post# 31304142

RE:RE:suckers bought at $10, can't handle the volatility should...

RE:RE:suckers bought at $10, can't handle the volatility should...
porksniffer wrote:
wagyusteak wrote: get the f out of here. 

https://tinyurl.com/y6m7y354

Pal:
08/11/1996: $1.5/share
03/05/2000: $9.65/share
02/03/2002: $10.5/share
12/01/2002: $3.6/share
03/06/2005: $4.1/share
10/27/2013: $63.79/share
02/16/2014: $145.25/share

LOL, what did we have during that period? 2 bubbles/recessions, one of them was a great financial crisis. LOL.

Naysayers will say "this time is differrent". 

Mug, don't waste your brain cells and energy on them. It's not worth it.


One problem.. The CEO no longer has the 'parent' for help you cuck. lmao This time is indeed different. You sound very frustrated lol, those days are but a memor, and a total fluke thanks to the 'parent' lol.


Everything Meir said would happen has happened. EVERYTHING



LOL haha. you seem like a Meir's cuck sucker. LOL. Do you know rockie and water head? What happened to them? I wonder? They are one of Meir's fan too. LOL
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities